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Abstract
Background: Prenatal testosterone (T) excess from days 30-90 of gestation disrupts gonadotropin surge and
ovarian follicular dynamics and induces insulin resistance and functional hyperandrogenism in sheep. T treatment
from days 60-90 of gestation produces a milder phenotype, albeit with reduced fecundity. Using this milder
phenotype, the aim of this study was to understand the relative postnatal contributions of androgen and insulin in
mediating the prenatal T induced disruptions in ovarian follicular dynamics.
Methods: Four experimental groups were generated: 1) control (vehicle treatment), 2) prenatal T-treated (100 mg i.
m. administration of T propionate twice weekly from days 60-90 of gestation), 3) prenatal T plus postnatal
anti-androgen treated (daily oral dose of 15 mg/kg/day of flutamide beginning at 8 weeks of age) and 4) prenatal T
and postnatal insulin sensitizer-treated (daily oral dose of 8 mg/day rosiglitazone beginning at 8 weeks of age).
Follicular response to a controlled ovarian stimulation protocol was tested during their third breeding season. Main
outcome measures included the determination of number and size of ovarian follicles and intrafollicular
concentrations of steroids.
Results: At the end of the controlled ovarian stimulation, the number of follicles approaching ovulatory size
(≥6 mm) were ~35 % lower in prenatal T-treated (6.5 ± 1.8) compared to controls (9.8 ± 2.0). Postnatal
anti-androgen (10.3 ± 1.9), but not insulin sensitizer (5.0 ± 0.9), treatment prevented this decrease. Preovulatory sized
follicles in the T group had lower intrafollicular T, androstenedione, and progesterone compared to that of the
control group. Intrafollicular steroid disruption was partially reversed solely by postnatal insulin sensitizer treatment.
Conclusions: These results demonstrate that the final preovulatory follicular growth and intrafollicular steroid milieu
is impaired in prenatal T-treated females. The findings are consistent with the lower fertility rate reported earlier in
these females. The finding that final follicle growth was fully rescued by postnatal anti-androgen treatment and
intrafollicular steroid milieu partially by insulin sensitizer treatment suggest that both androgenic and insulin
pathway disruptions contribute to the compromised follicular phenotype of prenatal T-treated females.
Keywords: Steroids, Testosterone, Androgen antagonist, Insulin sensitizer
* Correspondence: vasantha@umich.edu
1Department of Pediatrics, University of Michigan, 7641A Med Sci II, Ann
Arbor, MI 48109-5622, USA
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Veiga-Lopez et al. Journal of Ovarian Research  (2016) 9:39 
DOI 10.1186/s13048-016-0250-y
Background
With well over 5 million U.S. women affected, women with
polycystic ovary syndrome (PCOS) are frequent patients in
infertility clinics, seeking assistance in becoming pregnant
[1]. A PCOS diagnosis is reached when two of the follow-
ing three criteria are met: hyperandrogenism, oligo- or
anovulation, and/or polycystic ovaries [2–4]. The reduced
pregnancy rate in PCOS patients has been attributed to the
oligo-anovulatory condition of the syndrome; this, in part,
stems from a disrupted intrafollicular milieu, which in-
cludes reductions in cortisone [5], insulin growth like fac-
tor (IGF) I and II [6], and progesterone (P4) [7], increases
in anti-Mullerian hormone (AMH) [8], testosterone, andro-
stenedione, and proteomic dysregulation [9]. The compro-
mised intrafollicular steroidal milieu in PCOS women likely
accounts for the poor quality of oocytes [10, 11]. A recent
meta-analysis study found removal of oocytes from the dis-
rupted endogenous steroidal environment of PCOS women
and maturing them in vitro helps achieve better conception
rates [12]. Understanding the dysregulation of the intrafolli-
cular milieu is essential for developing strategies to over-
come infertility in PCOS.
Increasing evidence from several species (rhesus mon-
keys, sheep, rats, and mice) has demonstrated a link be-
tween prenatal exposure to testosterone (T) and
development of a PCOS-like phenotype [13, 14]. Specif-
ically, prenatal T-treatment disrupts the intrafollicular
steroidal balance in preovulatory follicles (5-7 mm) and
reduces embryonic potential in rhesus monkeys [11]. In
sheep, prenatal T excess from days 30 to 90 of gestation
(T30-90) enhances follicular recruitment and persistence
[13] and causes disruptions in several key mediators of
folliculogenesis [15–18]. A milder PCOS-like phenotype
with reduced fecundity was found in sheep treated pre-
natally from days 60-90 of gestation (T60-90), where
only 40 % of such prenatal T-treated females became
pregnant [19]. These T60-90 females also developed in-
sulin resistance [13].
Using the milder T60-90 phenotype [19] and a con-
trolled ovarian stimulation protocol that effectively
stimulates follicular development [20], we tested the
hypothesis that prenatal T excess compromises mat-
uration of the preovulatory follicle and disrupts the
intrafollicular milieu in sheep. Since i) prenatal T-
treated sheep manifest functional hyperandrogenism
and insulin resistance [13]; ii) treatment with an an-
drogen antagonist or insulin sensitizer improves ovu-
latory function in women with PCOS [21], the
reproductive phenotype of whom prenatal T-treated
sheep recapitulate; and iii) postnatal insulin
sensitizer-treatment prevents a progressive loss in cy-
clicity of prenatal T-treated sheep [22], this study
aimed to parse out the relative postnatal contribution
of androgen and insulin towards dysfunctional follicle
responses of T60-90 prenatal T-treated sheep to
controlled ovarian stimulation in adulthood.
Methods
Prenatal and postnatal treatments
All procedures used were approved by the Institutional
Animal Care and Use Committee of the University of
Michigan and conducted at the University of Michigan
Sheep Research Facility. Animal husbandry details have
been published previously [23]. Mature Suffolk ewes (2
to 3 years in age) maintained under a natural photo-
period were mated and date of mating confirmed based
on rump paint marks left by a raddled ram. Pregnant
ewes were blocked by weight and body score and ran-
domly assigned to one of two treatment groups: 36 ani-
mals in the prenatal T treatment group received
100 mg T propionate (Sigma-Aldrich Corp., St. Louis,
MO) twice weekly in 2 ml of corn oil, i.m. from days 60
to 90 of gestation, while 12 controls received an equal
volume of vehicle. Before puberty beginning at 8 weeks
of age, prenatal T-treated females received either andro-
gen antagonist, flutamide (Sigma-Aldrich, Corp.) (n = 11),
the insulin sensitizer, rosiglitazone (Avandia; GlaxoS-
mithKline, Durham, NC) (n = 12), or no treatment (n = 13).
Flutamide was administered orally at a dose of 15 mg/kg/
ewe/day and rosiglitazone orally at a dose of 0.11 mg/kg/
ewe/day as previously described [24].
Controlled ovarian stimulation
During their third breeding season (~2.5 years of age),
the follicular response to a controlled ovarian stimula-
tion protocol modified from that previously described
[25] was tested in all females (see Fig. 1a). All females
received 2 ml of prostaglandin F2α (PGF2α, 5 mg/ml;
Lutalyse, Pfizer Animal Health, MI) and an intravaginal
P4 control internal drug release device (CIDR; Eazi-
Breed CIDR sheep inserts, Pfizer Animal Health, NY) on
day 0 that was replaced on day 7. Beginning on day 1,
10 μg/kg body weight of acyline, a GnRH antagonist
(GnRHa) procured from the National Hormone and
Peptide Program, was administered every 12 h for
10 days. This was followed by administration of 8 de-
creasing doses (two doses at each concentration) of FSH
(0.6, 0.4, 0.3, and 0.1 mg/kg; Folltropin-V, Bioniche Ani-
mal Health, GA) starting on day 11. The P4 CIDR was
removed after the sixth FSH dose.
Follicular dynamics
To monitor changes in follicular dynamics, transrectal
ultrasonography was performed as previously described
[26] using a scanner (Aloka SSD-900 V, Aloka Co. Ltd.,
Wallington, CT) fitted to a 7.5 MHz linear array trans-
ducer. Number of follicles ≥ 2 mm and corpora lutea
were determined prior to the start of GnRHa treatment,
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after the last GnRHa dose, and after the 3rd and 6th FSH
dose (Fig. 1a). Two hours after the 8th FSH dose, a sub-
set (n = 6/group) of females were ovariectomized follow-
ing procedures previously described [27], and all
follicles ≥ 3 mm were dissected [20]. After recording
their diameter, follicular fluid was aspirated and frozen
at -20 °C. Prior to measurements, all follicular fluids
were diluted 1:100 in 1x PBS supplemented with 1 %
BSA. After follicular dissection and aspiration, the
collapsed follicle was not useful to undertake histological
studies.
Intrafollicular steroids
Follicular fluid concentrations of androstenedione (A4),
estradiol (E2), estrone, P4, and T were measured by
quadruple linear ion trap mass spectrometer (LC-MS/
MS) from one 3 mm, one 4 mm, and two 5-6 mm folli-
cles that were randomly selected from each
Fig. 1 a Scheme depicting synchronization and controlled ovarian stimulation protocol used in the study. See text for details. CIDR: intravaginal
P4 control internal drug release device, PGF2α: prostaglandin F2α, FSH: follicle stimulating hormone, GnRH: gonadotropin releasing hormone, OVX:
ovariectomy, replac.: replacement, US: transrectal ultrasonography. Grey and black arrows indicate time of GnRH antagonist and FSH
administration, respectively. b Mean (± SEM) number of 2-3 mm (top panel) and 4-6 mm (bottom panel) before GnRH antagonist (PreGnRHa), after
GnRH antagonist (PostGnRHa), before the 3rd and 6th FSH doses (FSH3 and FSH6, respectively), and ovariectomy (OVX) in control (white bars), T
(filled bars), T + F (dotted bars), and T + R (stripped dars) females. See Fig. 1 for synchronization and controlled ovarian stimulation protocol and text
for details of prenatal/postnatal treatment details. F: flutamide; R: rosiglitazone; n.s.: not significant; * P < 0.01, ** P < 0.001
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ovariectomized female. Samples (400 μl) were extracted
after diluting with ultrapure water (500 μl). An internal
deuterated standard and 1 ml of 2-methoxy-2-methyl-
propane was added to each sample, vortexed vigorously,
and incubated for 5 min at room temperature. The
steroid-containing organic phase was air-dried and re-
suspended in 100 μl of ethanol and 500 μl of water. A
second liquid-liquid extraction was performed with di-
chloromethane. The steroid-containing dichloromethane
phase was air-dried and samples re-suspended in
NaHCO3 buffer (25 μl), and estrone and E2 were derivi-
tized with 50 μl of dansyl chloride (200 mg/ml in aceto-
nitrile), heated to 40 °C for 4 min, and transferred into
minivials.
A4, T, E2, estrone, and P4 were assayed in the Assay
Services Laboratories at the Wisconsin National Primate
Research Center using a QTRAP 5500 LC-MS/MS (AB
Sciex, USA) equipped with an atmospheric pressure
chemical ionization source. The system included two
Shimadzu LC20ADXR pumps and a Shimadzu
SIL20ACXR autosampler. Thirty μl samples were
injected onto a Phenomenex Kinetex 2.6u C18 100A,
100 × 2.1 mm column (Phenomenex) for separation. LC-
MS/MS results were generated in positive-ion mode
with optimized voltages. Calibration curve concentra-
tions for estrogens were 1.56-0.003 ng/ml and 3.91-
0.0076 ng/ml ng/ml for remaining steroids. Linearity
was r > 0.9990 and curve fit was linear with 1/x weight-
ing. Interassay coefficients of variation were determined
by a pool of human serum and ranged from 6.09-
19.47 % for all steroids. Assay sensitivities for A4, E2, es-
trone, P4 and T were 0.015, 0.005, 0.0015, 0.015, and
0.0325 ng/ml, respectively.
Statistical analysis
For analyses of follicular dynamics, follicles were
grouped as 2-3 mm, 4-6 mm, ≥2 mm, ≥4 mm, and
≥6 mm follicles. For intrafollicular steroid measure-
ments, follicle classes included 3 mm, 4 mm, and 5-
6 mm in diameter. Follicle size distribution among treat-
ment groups and intrafollicular steroid concentrations
among follicular classes within each treatment group
and within a follicular class across treatment groups
were analyzed by ANOVA and linear mixed effect model
with Tukey posthoc tests. Percent change in intrafollicu-
lar steroid concentrations between 3 mm and 5-6 mm
follicles was derived by subtracting concentration in
3 mm from that in larger follicles. Appropriate transfor-
mations were applied, as needed, to account for normal-
ity of data allowing analyses by parametric tests. All
analyses were carried out using PASW Statistics for
Windows release 18.0.1 and data presented as mean ±
SEM. P < 0.05 was considered significant.
Results
Follicular size dynamics
GnRHa treatment decreased the number of 4-6 mm, but
not 2-3 mm, follicles (P < 0.001; Fig. 1b). FSH adminis-
tration increased number of 2-3 mm follicles (P < 0.001)
by the third dose followed by a decline by the 6th FSH
dose (P < 0.001). This decline in 2-3 mm was accom-
panied by a marked increase (P < 0.001) in the num-
ber of 4-6 mm follicles (P < 0.001). At ovariectomy, a
further decline in 2-3 mm follicles and an increase in
4-6 mm follicles (P < 0.001) were found. GnRHa- and
FSH-induced changes in 2-3 and 4-6 mm follicles in
all treatment groups did not differ from the control
group.
When all follicles ≥2 mm were considered, FSH in-
creased the total number of follicles by the third FSH
dose (P < 0.001; Fig. 2), increasing further until the sixth
FSH dose (P < 0.001) but not beyond. In contrast,
GnRHa administration significantly reduced ≥4 mm fol-
licles (P < 0.001; Fig. 2). An increase in ≥4 mm follicles
was observed following the third FSH dose and beyond
(P < 0.001). There were no differences in follicular
classes ≥2 mm and ≥4 mm between control and all
treatment groups.
An increase was evident by the sixth FSH dose in
≥6 mm follicles (P < 0.001), culminating in a 3-fold in-
crease at ovariectomy (P < 0.001; Fig. 2). Prenatal T
treatment reduced ≥6 mm follicle number, with an initial
decline evident by sixth FSH dose and achieving signifi-
cance at ovariectomy (Fig. 2). Postnatal treatment with
flutamide, but not rosiglitazone, prevented the prenatal
T-induced reduction in ≥6 mm follicles.
Intrafollicular steroids
Figure 3a shows changes in intrafollicular concentrations of
steroids. In control females, intrafollicular T concentrations
were higher in 3 mm vs. larger follicles (P < 0.05), while the
reverse was found for intrafollicular E2 and P4, with higher
concentrations found in 5-6 mm follicles (P < 0.05). Control
females had an increase in E2 with follicle size (P < 0.05)
that was not seen in T and T +R females. T + F females
had high E2 concentrations regardless of follicle size. There
was no follicle size effect on intrafollicular T and E2 concen-
trations in T and T + F females, while an increase in P4 was
evident in 5-6 mm follicles of T + R females.
No differences were found among treatment groups
with intrafollicular T, A4, estrone, E2, and P4 concentra-
tions in the different follicular classes. When analysis
was restricted only to control and T-treated females, T
females had lower T and P4 (P < 0.05) and tended to
have lower A4 (P = 0.07) in 5-6 mm follicles. Overall
evaluation of change in steroids between the 3 and 5-
6 mm sized follicles (Fig. 3b) revealed increases in A4,
estrone, E2, and P4 and a reduction in T in control
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females, while reductions in A4, estrone, and P4 were
observed in T females. The increase in E2 from 3 to 5-
6 mm was of a higher magnitude in control compared to
T females. The changes in A4, estrone, and E2 were
more pronounced in T + F than T females. The direc-
tionality of changes in steroids between 3 and 5-6 mm
in T + R females mirrored that of control females.
Comparison of steroid ratios across follicular stages
found the follicular androgen to estrogen ratios (T:E2, T +
A4:E2, T + A4:estrone + E2, and T:estrone + E2) in controls
were lower in 5-6 mm compared 3 mm follicles (P < 0.05)
(Fig. 4). The T:E2 and T +A4:E2 ratios were also lower in
5-6 mm vs. 3 mm follicles in T females. Intrafollicular
T:E2, T + A4:E2, T + A4:estrone + E2, and T:estrone + E2
ratios were all lower (P < 0.05) in 5-6 mm vs. 3 mm folli-
cles within the T + R group. No treatment effect was
found in steroid ratios. Data skewness prevented detection
of differences in T:E2 and T +A4:E2 ratios in T + F
females.
Discussion
This study is the first to demonstrate that prenatal T ex-
cess from days 60-90 of gestation impairs final preovula-
tory follicular growth (ovulatory size: ≥6 mm; [28]) and
reduces intrafollicular concentrations of T, A4, and P4 in
preovulatory sized follicles of sheep undergoing
Fig. 2 Mean (± SEM) number of ≥2 mm (top panel), ≥ 4 mm (middle panel), and≥ 6 mm (bottom panel) follicles before GnRH antagonist
(PreGnRHa), after GnRH antagonist (PostGnRHa), before the 3rd and 6th FSH dose (FSH3 and FSH6, respectively), and ovariectomy (OVX) in control
(C; white bars), T (filled bars), T + F (dotted bars), and T + R (stripped bars) females. See Fig. 1 for synchronization and controlled ovarian stimulation
protocol and text for prenatal/postnatal treatment details. F: flutamide; R: rosiglitazone; n.s.: not significant; * P < 0.01, ** P < 0.001. # represents
significant different (P < 0.05) compared to the control group
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controlled ovarian stimulation, a finding consistent
with the lower fertility rates reported in these sheep
[19]. The rescue of final growth by postnatal andro-
gen antagonist, but not insulin sensitizer, administra-
tion suggests the impairment of prevoulatory follicle
growth is mediated via androgenic action. This, in
concert with the partial rescue of the intrafollicular
steroid milieu with insulin sensitizer, suggests that
both androgens and insulin contribute to reproductive
disruption [29–31] and reduced fecundity [17] in
adult prenatal T-treated sheep.
Prenatal T programming of follicular dynamics
The GnRHa treatment regimen used was effective in
blocking follicular growth beyond the 3 mm stage in
both the control and prenatal T-treated sheep, as was
the case with T30-90 females exposed to a shorter
GnRHa treatment [32]. The efficacy of pFSH to recruit
follicular growth in controls was comparable to that
achieved with oFSH or pFSH stimulation in other sheep
breeds [25, 33]. pFSH used in this study was also as ef-
fective in stimulating follicular growth in the 3 treatment
groups (T, T + F, and T + R) as the combined oFSH- LH
Fig. 3 a Mean (± SEM) intrafollicular concentrations (ng/ml) of testosterone (T), androstenedione (A4), estrone, estradiol (E2), and progesterone
(P4) at the time of ovariectomy and coincidentally with the 8th FSH dose in control (C; yellow), prenatal testosterone-treated (T; red), prenatal T
plus postnatal flutamide (T + F; blue), and prenatal T plus postnatal rosiglitazone (T + R; gray) females. See Fig. 1 for synchronization and controlled
ovarian stimulation protocol and text for prenatal/postnatal treatment details. Within group comparisons: asterisks represent differences within
group within hormone and between follicular sizes. Posthoc analyses performed only when overall ANOVA among all three sizes was significant.
Comparisons between C and T group are represented by a ≠ b if P < 0.05 and by a’≠ b’if P = 0.07. F: flutamide; R: rosiglitazone. Data obtained
from one 3 mm, one 4 mm, and two 5-6 mm follicles randomly selected from each female. b Percent change in intrafollicular steroids of T, A4,
estrone, E2, and P4 between 3 and 5-6 mm follicles in C (yellow), T (red), T + F (blue), T + R (black) groups. Percent change was calculated
by subtracting the overall mean values between the 3 and 5-6 mm size within each group
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regimen used with T30-90 females [32]. These findings
indicate responsiveness to exogenous FSH, and hence
recruitment, was not impaired by prenatal T excess or
postnatal treatment with androgen antagonist or insulin
sensitizer. The finding that recruitment and growth of
follicles up to 4 mm size was similar across groups is
not surprising, because androgens increase FSH activity
[34] and are not detrimental to follicular survival and
growth of preantral and early antral follicles [35].
The reduced number of follicles ≥6 mm in T females
suggests the final maturation of the preovulatory follicle
is impaired. Given that i) the suppression was evident in
number of follicles ≥6 mm, but not in the number up to
4 mm, and ii) in sheep, follicles up to 4 mm size are
considered FSH dependent and those beyond 4 mm as
LH dependent [28], the shift from FSH to LH depend-
ency appears to be impaired. One possibility is that this
reduction in preovulatory sized follicles might be a func-
tion of advancement in LH dependency and hence a re-
quirement for LH. Because LH was not co-administered
with FSH, the final transition to preovulatory size might
be compromised. This premise is supported by the lack
of reduction in preovulatory sized follicles in the T30-90
females [32], when follicles were stimulated concomi-
tantly with LH and FSH. Findings from both studies
(this study and Steckler et al. [32]) suggest the compro-
mised preovulatory follicular development might be res-
cued with exogenous LH supplementation. It is unclear
if this impairment is a function of reduced number of
LH receptors or altered LH signaling, both are aspects
yet to be studied in this model but implicated in women
with PCOS [36–38].
Importantly, the fact that postnatal androgen antagonist,
not insulin sensitizer, treatment was able to rescue the
number of preovulatory-sized follicles supports the notion
that i) compromised androgen receptor expression/func-
tion in growing follicles or surrounding ovarian stroma is
detrimental to progression beyond a critical size (4 mm in
this case) and ii) that blockade of androgen action with an
androgen antagonist would help overcome follicular
growth arrest. In previous studies, we found prenatal T
treatment from days 30-90 of gestation increases granu-
losa cell androgen receptor expression in antral follicles
and is supportive of functional ovarian hyperandrogenism
[15]. Although insulin plays a role in follicular develop-
ment [39–41], failure of insulin sensitizer treatment to
rescue this follicular growth defect suggests this dysfunc-
tion is driven primarily by the androgen signaling imbal-
ance within the growing follicle.
Prenatal T programming of follicular steroid milieu
The opposing follicular size-related changes in intra-
follicular T and estrogens in control females were
similar to previous findings [20, 42]. A higher andro-
genic environment prevails in small follicles, with a
shift towards a highly estrogenic milieu in preovula-
tory follicles; this is consistent with increased aroma-
tase activity as follicles mature [42]. The transition
from low E2 in smaller follicles to high E2 in larger
follicles was the most striking change (4-fold increase)
in the control group. Conversely, the E2 increase was
of much lower magnitude (< 1-fold) in the T group.
Because androgens are the main substrate for estrogen
production, the reduced magnitude of E2 increase in T
females may be driven by a reduced androgenic environ-
ment (T and A4) at earlier follicular stages. Androgen and
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Fig. 4 Mean (± SEM) intrafollicular steroid ratios of testosterone
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within hormone and between follicular sizes. Posthoc analyses performed
only when overall ANOVA among all three sizes was significant. Data
obtained from one 3 mm, one 4 mm, and two 5-6 mm follicles randomly
selected from each female
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estrogen receptors [17] and steroidogenic enzymes [43]
are dysregulated in granulosa and theca cells of T30-90
sheep, and these disruptions remain to be determined in
T60-90 females. It is also unclear whether the lower mag-
nitude of E2 increase in T females contributes to the
delayed onset of LH surge that was reported earlier in
these females [29].
Prenatal T-induced disruptions in intrafollicular steroid
milieu were also reported in non-human primates [11].
Controlled ovarian stimulation studies in rhesus monkeys
found 15-35 days of T treatment starting on gestational
days 40-44, but not days 100-115, reduced intrafollicular
A4 and E2 concentrations in preovulatory sized follicles
[11]. Although disruptions in intrafollicular A4 and E2
parallel findings from the current study, timing and dur-
ation of T exposure differ between the sheep and monkey
study. Our earlier findings of reduced granulosa cell
CYP19A1 expression in antral follicles in the T30-90
model [43] agrees with the reduced intrafollicular E2 in
large antral follicles evidenced in the present study [43].
Considering the disrupted intrafollicular steroidal milieu
of prenatal T-treated monkeys was accompanied by a re-
duction in oocyte competence [11], a similar intrafollicular
disruption was evidenced in prenatal T-treated sheep is
likely to be associated with compromised oocyte health.
This, in fact, may explain the reduced fecundity in T60-90
females [19]. The strength of the present study is that the
intrafollicular steroid milieu was identified in different size
follicular classes as opposed to only the preovulatory fol-
licular size in monkeys. Another strength is the parallel as-
sessment of follicular growth at different time points
during the ovarian stimulation protocol, which was helpful
in dissecting out regulation of follicular growth from
steroidogenesis.
Relative to interventions, postnatal flutamide treatment
rescued follicular growth to where preovulatory follicle
size was achieved, but treatment failed to ameliorate the
disruptions in intrafollicular steroidal milieu. The steroidal
transition from low E2 to a high E2 milieu between 3 to
6 mm size antral follicles seen in controls was not evident
in T + F females. In addition, the directionality of change
in intrafollicular concentrations of estrone and A4 in T +
F animals, namely a reduction in both steroids in the
6 mm compared to 3 mm follicles as opposed to the
increase in both steroids in the controls, point to an intra-
follicular steroidal disruption that persists through antral
follicle growth. The increase of T in the smaller 3 mm
follicles of the T + F females may be a compensatory
response to the blockade of androgen receptor signaling
by flutamide treatment, which was present throughout the
course of the study. Such a response would be analogous
to the masculinizing effects of flutamide seen relative to
other variables [44, 45]. To what extent the intrafollicular
steroidal disruptions play a role in oocyte health and
ultimately fertility remains unclear. Paradoxically, while
flutamide treatment failed to ameliorate intrafollicular
steroidal defects, the same treatment prevented pubertal
advancement and enhanced preovulatory LH surge ampli-
tude in the T30-90 females [24]. Considering T is an aro-
matizable androgen, the differing effects of flutamide in
rescuing the various physiologic functions may be a func-
tion of whether androgen or estrogen (via aromatization)
is the programming agent [31].
Despite the fact that T60-90 females are insulin re-
sistant [13], the lack of rescue in the number of folli-
cles that achieved a preovulatory size by rosiglitazone
suggests the insulin pathway is not involved in growth
of preovulatory follicles. In contrast, the intrafollicular
steroid milieu of T + R follicles was more similar to
that of the controls and is supportive of a role for in-
sulin coupled with FSH as follicles mature in main-
taining intrafollicular steroid balance [46]. The
beneficial effects of insulin sensitizer therapies in
enhancing insulin sensitivity and improving ovulatory
function in women with PCOS [47, 48] may relate to
normalization of intrafollicular steroidal milieu, as
evidenced in the T + R animals.
In interpreting the impact of the interventions, it is im-
portant to recognize that GnRH antagonist treatment given
prior to FSH stimulation to achieve a homogeneous follicu-
lar pool before FSH stimulation (as achieved in this study,
Fig. 1) might have played a role in determining the impact
of androgen antagonist and insulin sensitizer on follicular
dynamics and the intra-follicular hormone milieu. However,
considering that GnRH antagonist treatment is the same
across treatments, any variability in the starting pool of fol-
licles across treatment would suggest intrinsic ovarian
differences originating from the T treatment and interven-
tions respectively. It needs to be recognized that GnRH
agonist and antagonist treatments are routinely used in
standard IVF practices [49], and hence the approach taken
with this study is consistent with this practice.
The outcomes achieved with the two interventions,
namely the androgen antagonist helping rescue follicular
growth and the insulin sensitizer partially rescuing intra-
follicular steroidal milieu, suggest that both androgens
and insulin may synergize in establishing optimal follicu-
lar growth and steroidogenesis. A combined intervention
involving both may help compensate for any deficiency
that one intervention has in order to achieve better suc-
cess. While the finding in PCOS women is that com-
bined treatment is more efficacious than monotherapies
in treating anovulation [50] is supportive of this possibil-
ity, this remains to be tested.
Conclusions
Prenatal T excess from days 60-90 of gestation impairs
final follicular growth and intrafollicular milieu under
Veiga-Lopez et al. Journal of Ovarian Research  (2016) 9:39 Page 8 of 10
controlled ovarian stimulation protocols. This indicates
an inherent ovarian defect that may contribute to the
lower fertility seen in these females [19]. The differential
benefit of postnatal androgen antagonist and insulin
sensitizer treatment in rescuing follicular growth and
steroidogenesis, respectively, raises the possibility that
combined therapies during adolescence and early adult-
hood may be beneficial in enhancing fertility, a premise
that remains to be tested.
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